nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adjusting for covariates in evaluating markers for selecting treatment, with application to guiding chemotherapy for treating estrogen-receptor-positive, node-positive breast cancer
|
Janes, Holly |
|
2017 |
63 |
C |
p. 30-39 10 p. |
artikel |
2 |
Bayesian clinical trial design using Markov models with applications to autoimmune disease
|
Eggleston, Barry S. |
|
2017 |
63 |
C |
p. 73-83 11 p. |
artikel |
3 |
Blinded sample size recalculation in clinical trials incorporating historical data
|
Hees, Katharina |
|
2017 |
63 |
C |
p. 2-7 6 p. |
artikel |
4 |
Dose-ranging design and analysis methods to identify the minimum effective dose (MED)
|
Zhou, Yijie |
|
2017 |
63 |
C |
p. 59-66 8 p. |
artikel |
5 |
Editorial board
|
|
|
2017 |
63 |
C |
p. iii- 1 p. |
artikel |
6 |
Increasing the efficiency of oncology basket trials using a Bayesian approach
|
Liu, Rong |
|
2017 |
63 |
C |
p. 67-72 6 p. |
artikel |
7 |
Innovative Designs, Methods and Application for Disease Risk Prediction and Drug Development: Frequentist, Bayesian, and Beyond
|
|
|
2017 |
63 |
C |
p. 1- 1 p. |
artikel |
8 |
Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale
|
Satagopan, Jaya M. |
|
2017 |
63 |
C |
p. 40-50 11 p. |
artikel |
9 |
Optimal adaptive group sequential design with flexible timing of sample size determination
|
Cui, Lu |
|
2017 |
63 |
C |
p. 8-12 5 p. |
artikel |
10 |
Sequential designs for individualized dosing in phase I cancer clinical trials
|
Mao, Xuezhou |
|
2017 |
63 |
C |
p. 51-58 8 p. |
artikel |
11 |
Statistical design for a confirmatory trial with a continuous predictive biomarker: A case study
|
Joshi, Adarsh |
|
2017 |
63 |
C |
p. 19-29 11 p. |
artikel |
12 |
The application of group sequential stopping boundaries to evaluate the treatment effect of an experimental agent across a range of biomarker expression
|
Holmgren, Eric |
|
2017 |
63 |
C |
p. 13-18 6 p. |
artikel |